Asco 2019 – Polo reveals an overall survival hole | Evaluate
Sotorasib in KRAS p.G12C-mutated Pancreatic Cancer
POLO Trial Shows Maintenance Olaparib Improves PFS in Metastatic Pancreatic Cancer - The ASCO Post
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
HCP's Thoughts On Pancreatic Cancer | Knowledge | CREATION.co
POLO trial is back | OS is negative | But the manuscript is full SPIN CYCLE | Insane! - YouTube
POLO trial for advanced pancreatic cancer: a | EurekAlert!
LYNPARZA® (olaparib) Efficacy for Metastatic Pancreatic Cancer
Olaparib for Pancreatic Cancer with BRCA Mutations - NCI
Olaparib maintenance therapy improves PFS in BRCA-mutated metastatic pancreatic cancer | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
Asco 2019 – Polo reveals an overall survival hole | Evaluate
Dr. Antonio Calles 🫁🚭 on Twitter: "LBA4 POLO trial: olaparib maintenance in germline BRCA mutant pancreatic adenocarcinoma. Nice data but... PFS as primary endpoint comparing active drug vs no treatment is not
Dr Amol Akhade on Twitter: "19 vs 19.2 . POLO . Metastatic pancrease ca. Once again Placebo arm has longer OS than Olaparib. I really appreciate the positive spin off by medical
Trial results PARP inhibitors in pancreatic cancer | Download Scientific Diagram
![ASCO-GI 2021: [VIRTUAL] Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.](https://larvolclin.s3.us-west-2.amazonaws.com/resize_16206080921308275236098845c20171.jpeg "ASCO-GI 2021: [VIRTUAL] Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.")
ASCO-GI 2021: [VIRTUAL] Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
Diagnostics | Free Full-Text | Surveillance of Individuals with a Family History of Pancreatic Cancer and Inherited Cancer Syndromes: A Strategy for Detecting Early Pancreatic Cancers
ASCO GI 2021: Results From the Phase 3 POLO Trial
Cancer Trial Results
Expanding PARP Inhibitor Benefits in Advanced Pancreatic Cancer | MedPage Today
Phase III POLO Trial - Slideset Download - Clin Onc June 2019 | CCO
A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial) | SpringerLink
NCCN Guidelines Updates: Pancreatic Cancer in: Journal of the National Comprehensive Cancer Network Volume 17 Issue 5.5 (2019)
Dr. Antonio Calles 🫁🚭 on Twitter: "LBA4 POLO trial: olaparib maintenance in germline BRCA mutant pancreatic adenocarcinoma. Nice data but... PFS as primary endpoint comparing active drug vs no treatment is not
A trial of olaparib for pancreatic cancer that has spread (POLO) | Cancer Research UK
Maintenance rucaparib shows benefit in broader group of patients with pancreatic cancer
